MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze JAZZ →
    • FindStock Picks / Stock Screener
    • Value · JAZZIntrinsic Value Calculator
    • Invest · JAZZInvestment Case
    • Hold · JAZZ5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
JAZZ

JAZZ

Jazz Pharmaceuticals plc

$230.26
-6.19
 (-2.62%)
Exchange:  NASDAQ
Market Cap:  14.78B
Shares Outstanding:  60.984M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Renee D. Gala
Full Time Employees:  2890
Address: 
Waterloo Exchange
Dublin
DU
D04 E5W7
IE
Website:  https://www.jazzpharma.com
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
JAJAZZ logoJAZZJazz Pharmaceuticals plc14.8B64.315.47.2%
BBBBIO logoBBIOBridgeBio Pharma, Inc.14.8B——-23.6%
NBNBIX logoNBIXNeurocrine Biosciences, Inc.15.2B21.620.514.3%
EXEXEL logoEXELExelixis, Inc.16.2B18.721.739.7%
ASASND logoASNDAscendis Pharma A/S16.6B16.215.411.4%
BMBMRN logoBMRNBioMarin Pharmaceutical Inc.11.7B—14.5-1.0%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/02 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue3,834,2044,068,9504,267,586
Gross Profit3,398,6273,623,2373,764,290
EBITDA1,449,4221,521,711262,757
Operating Income578,580716,630224,421
Net Income414,832560,120-356,148

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets11,393,35912,012,25711,659,340
Total Liabilities7,656,3627,918,5017,340,756
Total Stockholders Equity3,736,9974,093,7564,318,584
Total Debt5,791,6146,162,3571,080,795
Cash and Cash Equivalents1,506,3102,412,8641,391,899

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow1,092,0071,395,9081,355,773
Capital Expenditure-23,962-48,070-209,752
Free Cash Flow1,068,0451,347,8381,146,021
Net Income414,832560,120-356,148
Net Change in Cash624,828906,554-1,020,965

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)5,964,646.294Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)6,463,413.712Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)6,251,099.837Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)3,012,023.248Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)3,274,127.793Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)3,162,555.897Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)1,973,361.805Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)2,191,015.802Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)2,098,365.485Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)2,351,358.587Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)2,547,980.649Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)2,464,283.137Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)34.410Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)35.930Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)32.360Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)15Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
4.069B  ?P/S
 (TTM)
: 
3.13
?Net Income
 (TTM)
: 
560.12M  ?P/E
 (TTM)
: 
64.32
?Enterprise Value
 (TTM)
: 
18.389B  ?EV/FCF
 (TTM)
: 
11.69
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
4.62%  ?ROIC
 (TTM)
: 
7.24%
?Net Debt
 (TTM)
: 
3.174B  ?Debt/Equity
 (TTM)
: 
1.35
?P/B
 (TTM)
: 
3.55  ?Current Ratio
 (TTM)
: 
1.82

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
15.42Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates JAZZ intrinsic value between $424.69 – $772.98 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate JAZZ Intrinsic Value

Common questions about JAZZ valuation

Is Jazz Pharmaceuticals plc (JAZZ) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Jazz Pharmaceuticals plc (JAZZ) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is JAZZ a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether JAZZ trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is JAZZ’s P/E ratio?

You can see JAZZ’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for JAZZ?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is JAZZ a good long-term investment?

Whether JAZZ fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Jazz Pharmaceuticals plc

  • Jazz Pharmaceuticals plc intrinsic value calculatorEstimate what the business is worth
  • Jazz Pharmaceuticals plc 5-year outlookWhat has to go right, and what could go wrong
JAZZ

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-2.62
MarketSnap

Trading Metrics:

Open: 233.99   Previous Close: 236.45
Day Low: 227.95   Day High: 238.1
Year Low: 156.95   Year High: 266.38
Price Avg 50: 229.05   Price Avg 200: 221.53
Volume: 984644   Average Volume: 852135

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
09-11-2026 10:16
Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
02-11-2026 21:58
Jazz Pharmaceuticals plc (JAZZ) Q3 2026 Earnings Call Transcript
Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates
02-11-2026 18:25
Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
23-10-2026 10:15
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
19-10-2026 16:15
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?
16-10-2026 10:20
Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze JAZZ →
    • FindStock Picks / Stock Screener
    • Value · JAZZIntrinsic Value Calculator
    • Invest · JAZZInvestment Case
    • Hold · JAZZ5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.